<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2230">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132127</url>
  </required_header>
  <id_info>
    <org_study_id>LTS17352</org_study_id>
    <secondary_id>U1111-1266-5421</secondary_id>
    <nct_id>NCT05132127</nct_id>
  </id_info>
  <brief_title>Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan</brief_title>
  <official_title>An Open-label Study for Sutimlimab in Participants With Cold Agglutinin Disease (CAD) Who Have Completed the CARDINAL Study (BIVV009-03/EFC16215, Part B) or CADENZA Study (BIVV009-04/EFC16216, Part B) in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, single treatment-group, open-label study to provide sutimlimab to the&#xD;
      adult participants with cold agglutinin disease (CAD) who have completed the CARDINAL or&#xD;
      CADENZA studies, and benefitted from sutimlimab treatment in Japan.&#xD;
&#xD;
      • Study and treatment duration: the period between the participant's completion of the&#xD;
      CARDINAL and CADENZA studies and sutimlimab or other appropriate CAD therapy becoming&#xD;
      commercially available to participants in Japan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The period between screening/baseline visit (upon the participant's completion* of the&#xD;
      CARDINAL and CADENZA studies) and end of treatment with sutimlimab in this study is&#xD;
      determined by sutimlimab or other appropriate CAD therapy becoming commercially available to&#xD;
      participants in Japan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2021</start_date>
  <completion_date type="Anticipated">June 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Cold Agglutinin Disease</condition>
  <arm_group>
    <arm_group_label>sutimlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Japan with CAD who have completed CARDINAL or CADENZA studies will receive sutimlimab (BIVV009). The dosing schedule consists of an initial dose (Day 0), followed by a dose one week later (Day 7), which is followed by a maintenance dose every other week beginning on Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sutimlimab</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: intravenous(iv)</description>
    <arm_group_label>sutimlimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        --Participant must be adults.&#xD;
&#xD;
          -  Participants who have been enrolled in, and has completed Part B of CARDINAL or&#xD;
             CADENZA study&#xD;
&#xD;
          -  Participants who have ongoing diagnosis of CAD&#xD;
&#xD;
          -  Participants who continue to require treatment for CAD upon completion of&#xD;
             participation in the previous study evidenced by return of CAD-related symptoms of&#xD;
             anemia and/or deterioration on markers of hemolysis after the end of study visit&#xD;
             following the 9-week safety follow up period. (9-week follow up period).&#xD;
&#xD;
          -  Participants who have acceptable benefit/risk profile&#xD;
&#xD;
          -  Participant who has acceptable infection risk&#xD;
&#xD;
          -  Participants who have no available appropriate alternative therapy for CAD&#xD;
&#xD;
          -  Body weight of ≥39 kg&#xD;
&#xD;
          -  Giving signed informed consent - - - -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        --Clinical diagnosis of systemic SLE or immune complex mediated autoimmune disorders&#xD;
&#xD;
          -  Participants who meet recent Rituximab and/or immunosuppressive therapy&#xD;
&#xD;
          -  Any of the following medical conditions:&#xD;
&#xD;
               1. Active, serious intercurrent illness which will preclude enrolment until recovery&#xD;
                  is complete.&#xD;
&#xD;
               2. Pregnancy or breast-feeding&#xD;
&#xD;
          -  End of Study visit in CARDINAL or CADENZA took place more than 3 months before&#xD;
             baseline visit in this study.&#xD;
&#xD;
          -  Hypersensitivity reactions to sutimlimab or components thereof, or other allergy that,&#xD;
             in the opinion of the Investigator, contraindicates participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>1 then #</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 3920005</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920004</name>
      <address>
        <city>Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920003</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920002</name>
      <address>
        <city>Saitama</city>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920001</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

